Thus, despite the high frequency of TCF-1+ CD8+ T cells within BrMs, these cells are phenotypically diverse and TCF-1 expression alone may not be an adequate marker of tumor-specific CD8+ T cell progenitor function. This evidence concerns the gene CD8A and neoplasm.